Magnetic resonance imaging of multiple sclerosis

Journal of Neuroimaging

Volumn 12, Issue 4, 2002, Pages 289-301

  Filippi, Massimo ^a   Tortorella, Carla ^a   Rovaris, Marco ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Diffusion weighted magnetic resonance imaging; Functional magnetic resonance imaging; Magnetic resonance spectroscopy; Magnetization transfer magnetic resonance imaging; Multiple sclerosis

Indexed keywords

CHOLINE; CREATINE; CREATINE PHOSPHATE; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT;

AXONAL INJURY; BRAIN CORTEX; DEMYELINATION; DIFFUSION WEIGHTED IMAGING; DISEASE SEVERITY; GRAY MATTER; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; QUANTITATIVE DIAGNOSIS; REVIEW; SPINAL CORD LESION; TREATMENT OUTCOME; WHITE MATTER;

EID: 0036785110     PISSN: 10512284     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2002.tb00136.x     Document Type: Review

References (149)

1. Rovaris M, Filippi M. Magnetic resonance techniques to monitor disease evolution and treatment trial outcomes in multiple sclerosis. Curr Opinions Neurol 1999;12:337-344.
2. Filippi M, Horsfield MA, Ader HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998;43:499-506.
3. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced MRI for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Lancet 1999;353:964-969.
4. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43:332-339.
5. Molyneux PD, Barker GJ, Barkhof F, et al. Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology 2001;57:2191-2197.
6. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-164.
7. Filippi M, Grossman RI, Comi G, eds. Magnetization transfer in multiple sclerosis. Neurology 1999;53(suppl 3).
8. Filippi M, Inglese M. Overview of diffusion-weighted magnetic resonance studies in multiple sclerosis. J Neurol Sci 2001;186(suppl 1):S37-S43.
9. Filippi M, Arnold DL, Comi G, eds. Magnetic Resonance Spectroscopy in Multiple Sclerosis. Milan, Italy: Springer-Verlag; 2001.
10. Yousry TA, Berry I, Filippi M. Functional magnetic resonance imaging in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):S85-S87.
11. Filippi M, Rocca MA. Functional magnetic resonance imaging. In: Filippi M, Comi G, eds. Primary Progressive Multiple Sclerosis. Heidelberg, Germany: Springer-Verlag; 2002:111-124.
12. Fazekas F, Barkhof F, Filippi M, et al. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology 1999;53:448-456.
13. Paty DW, Oger JJF, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180-185.
14. Fazekas F, Offenbacher H, Fuchs S, et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988;38:1822-1825.
15. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34:661-669.
16. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 200l;50:121-127.
17. Barkhof F, Filippi M, Miller DH, et al. Comparison of MR imaging criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059-2069.
18. Tintorè M, Rovira A, Martinez M, et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000;21:702-706.
19. Brex PA, Miszkiel KA, O'Riordan JI, et al. Assessing the risk of early multiple sclerosis in patients with clinically isolated syndromes: the role of a follow up MRI. J Neurol Neurosurg Psychiatry 2001;70:390-393.
20. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1 a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898-904.
21. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-1582.
22. Brex PA, O'Riordan JI, Miszkiel KA, et al. Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 1999;53:1184-1190.
23. Thorpe JW, Kidd D, Moseley IF, et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996;119:709-714.
24. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-835.
25. Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coil and fast spin echo: II: findings in multiple sclerosis. Neurology 1993;43:2632-2637.
26. Tartaglino LM, Friedman DP, Flander AE, Lublin FD, Knobler RL, Liem M. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 1995;195:725-732.
27. Lycklama à Nijeholt GJ, Barkhof F, Scheltens P, et al. MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. Am J Neuroradiol 1997;18:1041-1048.
28. Lycklama à Nijeholt GJ, Castelijns JA, Ader H, van Waesberghe JHTM, Polman C, Barkhof F. Sagittal MR of multiple sclerosis in the spinal cord: fast versus conventional spin-echo imaging. Am J Neuroradiol 1998;19:355-360.
29. Rocca MA, Mastronardo G, Horsfield MA, et al. Comparison of three MR sequences for the detection of cervical cord lesions in multiple sclerosis. Am J Neuroradiol 1999;20:1710-1716.
30. Lycklama à Nijeholt GJ, van Walderveen MAA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis: correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998;121:687-697.
31. Gass A, Filippi M, Rodegher ME, Schwartz A, Comi G, Hennerici MG. Characteristic of chronic MS lesions in the cerebrum, brainstem and spinal cord and optic nerve on T1-weighted MRI. Neurology 1998;50:548-550.
32. Bakshi R, Kinkel PR, Mechtler LL, et al. Magnetic resonance imaging findings in 22 cases of myelitis: comparison between patients with and without multiple sclerosis. Eur J Neurol 1998;5:35-48.
33. Filippi M, Rocca MA, Moiola L, et al. MRI and magnetization transfer imaging changes in the brain and cervical cord of patients with Devic's neuromyelitis optica. Neurology 1999;53:1705-1710.
34. Inglese M, Salvi F, Iannucci G, Mancardi G, Mascalchi M, Filippi M. Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. Am J Neuroradiol 2002;23:267-272.
35. Rovaris M, Viti B, Ciboddo G, Capra R, Filippi M. Cervical cord magnetic resonance imaging findings in systemic immune-mediated diseases. J Neurol Sci 2000;176:128-130.
36. Campi A, Filippi M, Comi G, Scotti G. Recurrent transverse myelopathy associated with anticardiolipin antibodies. Am J Neuroradiol 1998;19:781-786.
37. Moseley IF, Miller DH, Gass A. The contribution of magnetic resonance imaging to the assessment of optic nerve and spinal cord involvement in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64(suppl 1):S15-S20.
38. Filippi M, Grossman RI. MRI techniques to monitor MS evolution: the present and the future. Neurology 2002;58:1147-1153.
39. Filippi M. In-vivo tissue characterization of multiple sclerosis and other white matter diseases using magnetic resonance based techniques. J Neurol 2001;248:1019-1029.
40. Rovaris M, Viti B, Ciboddo C, et al. Brain involvement in systemic immune-mediated diseases: a magnetic resonance and magnetization transfer imaging study. J Neurol Neurosurg Psychiatry 2000;68:170-177.
41. Rocca MA, Colombo B, Pratesi A, Comi G, Filippi M. A magnetization transfer imaging study of the brain in patients with migraine. Neurology 2000;54:507-509.
42. Rovaris M, Holtmannspötter M, Rocca MA, et al. Contribution of cervical cord MRI and brain magnetization transfer imaging to the assessment of individual patients with multiple sclerosis: a preliminary study. Multiple Sclerosis 2002;8:52-58.
43. Rovaris M, Filippi M. The value of new magnetic resonance techniques in multiple sclerosis. Curr Opinions Neurol 2000;13:249-254.
44. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44:635-641.
45. Sailer M, O'Riordan JI, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999;52:599-606.
46. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow up study. Neurology 1995;45:255-260.
47. Davie CA, Hawkins CP, Barker GJ, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117:49-58.
48. De Stefano N, Matthews PM, Arnold DL. Reversible decreases in N-acetylaspartate after acute brain injury. Magn Reson Med 1995;34:721-727.
49. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal-appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998;43:809-814.
50. Goodkin DE, Rooney WD, Sloan R, et al. A serial study of new MS lesions and the white matter from which they arise. Neurology 1998;51:1689-1697.
51. Silver NC, Lai M, Symms MR, Barker GJ, McDonald WI, Miller DH. Serial magnetization transfer imaging to characterize the early evolution of new MS lesions. Neurology 1998;51:758-764.
52. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesion development in multiple sclerosis: longitudinal observation with T1-weighted spin-echo and magnetization transfer MR. Am J Neuroradiol 1998;19:675-683.
53. Filippi M, Rocca MA, Rizzo G, et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different doses of gadolinium. Neurology 1998;50:1289-1293.
54. Lai HM, Davie CA, Gass A, et al. Serial magnetisation transfer ratios in gadolinium-enhancing lesions in multiple sclerosis. J Neurol 1997;244:308-311.
55. Filippi M, Comi G. Magnetization transfer ratio changes in a symptomatic lesion of a patient at presentation with possible multiple sclerosis. J Neurol Sci 1997;151:79-81.
56. Dousset V, Gayou A, Brochet B, Caillé JM. Early structural changes in acute MS lesions assessed by serial magnetization transfer studies. Neurology 1998;51:1150-1155.
57. Rocca MA, Mastronardo G, Rodegher M, Comi G, Filippi M. Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. Am J Neuroradiol 1999;20:821-827.
58. Filippi M, Sormani MP, Rovaris M, Comi G. Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging. Magn Reson Imaging 1999;7:979-984.
59. Werring DJ, Clark CA, Barker GJ, Thompson AJ, Miller DH. Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology 1999;52:1626-1632.
60. Filippi M, Iannucci G, Cercignani M, Rocca MA, Pratesi A, Comi G. A quantitative study of water diffusion in MS lesions and normal-appearing white matter using echoplanar imaging. Arch Neurol 2000;57:1017-1021.
61. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001;56:304-311.
62. Rocca MA, Cercignani M, Iannucci G, Comi G, Filippi M. Weekly diffusion-weighted imaging study of NAWM in MS. Neurology 2000;55:882-884.
63. Werring DJ, Brassat D, Droogan AG, et al. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis. Brain 2000;123:1667-1676.
64. Arnold DL, Matthews PM, Francis GS, O'Connor J, Antel JP. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann Neurol 1992;31:235-241.
65. Truyen L, van Waesberghe JHTM, van Walderveen MAA, et al. Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 1996;47:1469-1476.
66. Gass A, Barker GJ, Kidd D, et al. Correlation of magnetization transfer ratio with disability in multiple sclerosis. Ann Neurol 1994;36:62-67.
67. Mainero C, De Stefano N, Iannucci G, et al. Correlates of MS disability assessed in-vivo using aggregates of MR quantities. Neurology 2001;56:1331-1334.
68. Allen IV, McKeown SR. A histological histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci 1979;41:81-91.
69. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
70. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000;123:1845-1849.
71. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998;43:56-71.
72. Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 1999;52:588-594.
73. Tortorella C, Viti B, Bozzali M, et al. A magnetization transfer histogram study of normal appearing brain tissue in multiple sclerosis. Neurology 2000;54:186-193.
74. Filippi M, Campi A, Dousset V, et al. A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology 1995;45:478-482.
75. Rovaris M, Filippi M, Falautano M, et al. Relation between MR abnormalities and patterns of cognitive impairment in multiple sclerosis. Neurology 1998;50:1601-1608.
76. Fu L, Matthews PM, De Stefano N, et al. Imaging of axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998;121:103-113.
77. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;63:736-742.
78. Nusbaum AO, Tang CY, Wei TC, Buchsbaum MS, Atlas SW. Whole-brain diffusion MR histograms differ between MS subtypes. Neurology 2000;54:1421-1426.
79. De Stefano N, Matthews PM, Fu L, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis: results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469-1477.
80. Filippi M, Tortorella C, Rovaris M, et al. Changes in the normal-appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:157-161.
81. Kidd D, Barkhof F, McConnel R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999;122:17-26.
82. Peterson JW, Bo L, Mork S, et al. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001;50:389-400.
83. Catalaa I, Fulton JC, Zhang X, et al. MR imaging quantitation of gray matter involvement in multiple sclerosis and its correlation with disability measures and neurocognitive testing. Am J Neuroradiol 1999;20:1613-1618.
84. Bakshi R, Ariyaratana S, Benedict RHB, Jacobs L. Fluid-attenuated inversion recovery magnetic resonance imaging detects cortical and juxtacortical multiple sclerosis lesions. Arch Neurol 2001;58:742-748.
85. Bakshi R, Benedict RHB, Bermel RA, et al. T2 hypointensity in the deep gray matter of patients with multiple sclerosis. Arch Neurol 2002;59:62-68.
86. Ge Y, Grossman RI, Udupa JK, Babb JS, Nyúl LG, Kolson DL. Brain atrophy in relapsing-remitting multiple sclerosis: fractional volumetric analysis of gray matter and white matter. Radiology 2001;220:606-610.
87. Cercignani M, Bozzali M, Iannucci G, Comi G, Filippi M. Magnetization transfer ratio and mean diffusivity of normal-appearing white and gray matter from patients with MS. J Neurol Neurosurg Psychiatry 2000;70:311-317.
88. Ge Y, Grossman RI, Udupa JK, Babb JS, Kolson DL, McGowan JC. Magnetization transfer ratio histogram analysis of gray matter in relapsing-remitting multiple sclerosis. Am J Neuroradiol 2001;22:470-475.
89. Rovaris M, Iannucci G, Falautano M, et al. Cognitive dysfunction in patients with mildly disabling relapsing-remitting MS: an exploratory study with diffusion tensor MR imaging. J Neurol Sci 2002;195:103-109.
90. Rovaris M, Filippi M, Minicucci L, et al. Cortical/ subcortical disease burden and cognitive impairment in multiple sclerosis. Am J Neuroradiol 2000;21:402-408.
91. Miki Y, Grossman RI, Udupa JK, et al. Isolated U-fiber involvement in MS: preliminary observations. Neurology 1998;50:1301-1306.
92. Bakshi R, Miletich RS, Kinkel PR, Emmet ML, Kinkel WR. High-resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis. J Neuroimaging 1998;8:228-234.
93. Blinkenberg M, Jensen CV, Holm S, Paulson OB, Sørensen PS. A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology 1999;53:149-153.
94. 18F] FDG PET study. NeuroImage 1996;4:87-96.
95. Filippi M, Bozzali M, Horsfield MA, et al. A conventional and magnetization transfer MRI study of the cervical cord in patients with multiple sclerosis. Neurology 2000;54:207-213.
96. Rovaris M, Bozzali M, Santuccio G, et al. Relative contributions of brain and cervical cord pathology to MS disability: a study with MTR histogram analysis.J Neurol Neurosurg Psychiatry 2000;69:723-727.
97. Reddy H, Narayanan S, Arnoutelis R, et al. Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 2000;123:2314-2320.
98. Reddy H, Narayanan S, Matthews PM, et al. Relating axonal injury to functional recovery in MS. Neurology 2000;54:236-239.
99. Lee M, Reddy H, Johansen-Berg H, et al. The motor cortex shows adaptive functional changes to brain injury from multiple sclerosis. Ann Neurol 2000;47:606-613.
100. Filippi M, Rocca MA, Falini A, et al. Correlations between structural CNS damage and functional MRI changes in primary progressive MS. NeuroImage 2002;15:537-546.
101. Filippi M, Rocca MA, Colombo B, et al. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. NeuroImage 2002;15:559-567.
102. Rocca MA, Falini A, Colombo B, Scotti G, Comi G, Filippi M. Adaptive functional changes in the cerebral cortex of patients with nondisabling MS correlate with the extent of brain structural damage. Ann Neurol 2002;51:330-339.
103. Rocca MA, Matthews PM, Caputo D, et al. Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology 2002;58:866-872.
104. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119:2009-2019.
105. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Neurology 1999;53:1698-1704.
106. Fox NC, Jenkins R, Leary SM, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology 2000;54:807-812.
107. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125:327-337.
108. van Buchem MA, McGowan JC, Kolson DL, Polansky M, Grossman RI. Quantitative volumetric magnetization transfer analysis in multiple sclerosis: estimation of macroscopic and microscopic disease burden. Magn Reson Med 1996;36:632-636.
109. van Buchem MA, Grossman RI, Armstrong C, et al. Correlation of volumetric magnetization transfer imaging with clinical data in MS. Neurology 1998;50:1609-1617.
110. Kalkers NF, Hintzen RQ, van Waesberghe JH, et al. Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy. J Neurol Sci 2001;184:155-162.
111. Cercignani M, Iannucci G, Rocca MA, Comi G, Horsfield MA, Filippi M. Pathologic damage in MS assessed in MS by diffusion weighted and magnetization transfer MRI. Neurology 2000;54:1139-1144.
112. Cercignani M, Inglese M, Pagani E, Comi G, Filippi M. Mean diffusivity and fractional anisotropy histograms in patients with multiple sclerosis. Am J Neuroradiol 2001;22:952-958.
113. Wilson M, Morgan PS, Lin X, Turner BP, Blumhardt LD. Quantitative diffusion weighted magnetic resonance imaging, cerebral atrophy, and disability in multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:318-322.
114. Arnold DL, Riess GT, Matthews PM, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994;36:76-82.
115. Matthews PM, Pioro E, Narayanan S, et al. Assessment of lesion pathology in multiple sclerosis using MRI morphometry and magnetic resonance spectroscopy. Brain 1996;119:715-722.
116. Gonen O, Catalaa I, Babb JS, et al. Total brain N- acetylaspartate: a new measure of disease load in MS. Neurology 2000;54:15-19.
117. Coles AJ, Wing MG, Molyneux P, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 1999;46:296-304.
118. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000;55:1714-1718.
119. Simon JH, Jacobs LD, Campion MK, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 1999;53:139-148.
120. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001;124:1803-1812.
121. Filippi M, Rossi P, Colombo B, Pereira C, Comi G. Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. Am J Neuroradiol 1997;18:1549-1556.
122. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16.
123. Barkhof F, Filippi M, Miller DH, Tofts P, Kappos L, Thompson AJ. Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997;244:76-84.
124. Filippi M, Dousset V, McFarland HF, Miller DH, Grossman RI. The role of MRI in the diagnosis and monitoring of multiple sclerosis: consensus report of the White-Matter Study Group of the International Society for Magnetic Resonance in Medicine. J Magn Reson Imaging 2002;15:499-504.
125. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998;43:79-87.
126. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: longterm efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-1636.
127. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001;49:290-297.
128. Sorensen PS, Wanscher B, Jensen CV, et al. Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 1998;50:1273-1281.
129. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K. Effect of interferon-beta 1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann Neurol 1999;46:850-859.
130. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000;54:1145-1155.
131. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999;53:751-757.
132. Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials. Brain 1998;121:2011-2020.
133. Miller DH, Barkhof F, Frank JA, Parker GJM, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125:1676-1695.
134. van Walderveen MAA, Kamphorst W, Scheltens P, et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998;50:1282-1288.
135. van Walderveen MAA, Barkhof F, Pouwels PJW, van Schijndel RA, Polman CH, Castelijns JA. Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 1999;46:79-87.
136. Wolansky LJ, Bardini JA, Cook SD, Zimmer AE, Sheffet A, Lee HJ. Triple-dose versus single-dose gadoteridol in multiple sclerosis patients. J Neuroimaging 1994;4:141-145.
137. Silver NC, Good CD, Sormani MP, et al. A modified protocol to improve the detection of enhancing brain and spinal cord lesions in MS. J Neurol 2001;248:215-224.
138. Filippi M, Rovaris M, Capra R, et al. Interferon beta treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology. J Neurol Neurosurg Psychiatry 1999;67:386-389.
139. Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Neurology 2000;55:185-192.
140. Barkhof F, van Waesberghe JH, Filippi M, et al. T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001;124:1396-1402.
141. Filippi M, Rovaris M, Rice GP, et al. The effect of cladribine on T1 "black hole" changes in progressive MS. J Neurol Sci 2000;176:42-44.
142. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 2000;123:2256-2263.
143. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001;57:731-733.
144. Brex PA, Molyneux PD, Smiddy P, et al. The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS. Neurology 2001;57:2185-2190.
145. Richert ND, Ostuni JL, Bash CN, Duyn JH, McFarland HF, Frank JA. Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon betalb. Am J Neuroradiol 1998;19:1705-1713.
146. Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Multiple Sclerosis 2001;7:49-58.
147. Kita M, Goodkin DE, Bacchetti P, Waubant E, Nelson SJ, Majumdar S. Magnetization transfer ratio in new MS lesions before and during therapy with IFNβ-1a. Neurology 2000;54:1741-1745.
148. Sarchielli P, Presciutti O, Tarducci R, et al. 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 1998;64:204-212.
149. Narayanan S, De Stefano N, Francis GS, et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 2001;248:979-986.